At ObsEva, our growth strategy includes the acquisition of additional clinical-stage assets, focusing either on new applications for existing drugs, or on new molecular entities that can address unmet needs for our patients. Clinical-stage assets of interest for ObsEva would meet the following Target Product Profile:
- Women’s reproductive health medicine
- Small chemical molecules, peptides, proteins, or mAbs
- Development stage: close to First-In-Man up to end-of-Phase2
- No generic drugs, unless innovative and proprietary delivery method and/or exclusivity
- License rights: preferably global
ObsEva’s review process has been designed to provide a rapid assessment of potential opportunities with the early involvement of our leadership. Our evaluation analysis relies on scientific criteria and business potential estimation.